A majority of healthcare professionals will not prescribe rosiglitazone for their patients with type 2 diabetes.
Ads by Google
Sex hormones play a significant role in the development of diabetic kidney disease.
MacroGenics's Protege trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes.
Roskamp Institute released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes.
Diabetes care providers found endocrinologists were universally aware of clinical tests that measure advanced glycation endproducts, a biomarker known to be elevated in people with diabetes.
It's never too early to focus on how to maintain good cardiovascular health, especially for people with type 1 diabetes.
American Diabetes Association strongly supports the legislation to ensure employees with diabetes and other diseases are given equal opportunity to work.
Most oral medications prescribed for type 2 diabetes are similarly effective for reducing blood glucose.
Study explains the physiologic benefits of diet and exercise on diabetes and beyond.
Little evidence supports using rosiglitazone (Avandia) to improve the quality or length of life among adults with diabetes.
Older, less-expensive diabetes drugs are equally as effective and safe as newer, costlier drugs.
Pediatrics researchers at The Children's Hospital of Philadelphia and McGill University in Montreal have identified a gene variant that raises a child's risk for type 1 diabetes, formerly called juvenile diabetes.
Thirty-nine clinic sites from 15 medical groups in Minnesota, North Dakota and Western Wisconsin have earned recognition for meeting diabetes treatment goals.
MedApps announces granting of regulatory clearance for over-the-counter use of the MedApps D-PAL Remote Patient Monitoring System for Diabetes by FDA.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes.
American Diabetes Association expressed its appreciation to Chicago Mayor Richard M. Daley for becoming the first U.S. mayor to formally recognize the UN Resolution on Diabetes.
Using a portion control plate helps diabetics both lose weight and decrease their reliance on medication.
New study further demonstrated the safety and efficacy of insulin Levemir (insulin detemir [rDNA origin] injection).
Alogliptin demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.
Over the last six years, Americans being treated for diabetes improved control of their disease by a significant 44.4 percent.
SYMLIN injection used in conjunction with basal insulin improved glucose control and reduced weight without increased hypoglycemia in patients with type 2 diabetes inadequately controlled with insulin glargine and oral agents.
Short-term interruptions of continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1 diabetes can result in significant elevations in blood glucose levels.
When added to metformin and/or a sulfonylurea, the once-a-day, long-acting insulin Lantus, significantly reduced free fatty acid levels in patients with type 2 diabetes compared to pioglitazone and had comparable effects to rosiglitazone.
BYETTA (exenatide) injection sustained improvements in blood sugar levels and progressive weight loss through three and a half years of therapy.
Study shows that the prevalence of diabetes rose 5% annually since 1990, and trends in incidence were consistent with the prevalence data.
Data from a sub-study of its Phase IIb multi-center clinical trial of Contrave demonstrated robust improvements in both visceral fat and insulin resistance.
An 8-year partnership among Centers for Disease Control and Prevention, North Carolina Department of Health and Human Services, Wake County Human Services resulted in a significant change in behavior related to diabetes prevention and care.
GlycoMark diabetes blood test is now available at major clinical reference laboratories nationwide.
Research underscored the utility of the GlycoMark 1,5-anhydroglucitol (1,5-AG) blood test to detect underlying treatment effects in patients with diabetes.